X4 Pharmaceuticals, Inc. (XFOR)
| Market Cap | 374.13M |
| Revenue (ttm) | 35.11M |
| Net Income (ttm) | -79.20M |
| Shares Out | 90.92M |
| EPS (ttm) | -1.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 244,662 |
| Open | 4.160 |
| Previous Close | 4.210 |
| Day's Range | 4.030 - 4.280 |
| 52-Week Range | 1.350 - 6.630 |
| Beta | 0.33 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+118.71%) |
| Earnings Date | May 4, 2026 |
About XFOR
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Ta... [Read more]
Financial Performance
In 2025, X4 Pharmaceuticals's revenue was $35.11 million, an increase of 1273.21% compared to the previous year's $2.56 million. Losses were -$79.20 million, 111.5% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for XFOR stock is "Strong Buy." The 12-month stock price target is $9.0, which is an increase of 118.71% from the latest price.
News
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on March...
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for ...
X4 Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Management overhaul and strategic refocus have streamlined operations and prioritized the 4WARD Phase III trial in chronic neutropenia, targeting a 2028 launch. Mavorixafor's oral formulation and favorable safety profile position it to address unmet needs in a 15,000-patient U.S. market.
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team...
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of p...
X4 Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Leadership has streamlined operations to focus on mavorixafor for chronic neutropenia, with a pivotal Phase III trial underway and enrollment targeted for completion by Q3. The therapy addresses significant unmet needs, offers an oral alternative to G-CSF, and has shown promising efficacy and safety data.
X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team wil...
X4 Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
A new management team has restructured operations, focusing on the 4WARD phase III trial for mavorixafor in chronic neutropenia, a market estimated at 15,000 US patients. The trial aims for top-line data in H2 2027, with commercialization targeted for 2028 and a premium pricing strategy.
X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team wil...
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Company's strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trial Previously announced workforce reductions resulted in $13M annualized cost savings ...
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million
BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the ...
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the ...
X4 Pharmaceuticals Announces Proposed Underwritten Public Offering
BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced that...
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M John Volpone appointed Chief Operating Officer, in ad...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on...
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement
BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today closed an upsized private pl...
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman, ...
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)
Poster #1654 highlights clinically meaningful and durable increases in circulating neutrophils observed with mavorixafor treatment +/- G-CSF over 6-month study Poster #1669 highlights findings that in...
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA
BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food...
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor
X4 Pharmaceuticals Earnings Call Transcript: Q1 2025
Q1 2025 saw strong clinical and commercial progress, with XOLREMDI sales reaching $3.5M and robust advancement in the 4WARD phase III CN trial. Cash reserves support operations into 2026, and new global partnerships and a U.S. patent strengthen future prospects.
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026
Top 3 Health Care Stocks That May Rocket Higher In April
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will repo...
X4 Pharmaceuticals Announces Reverse Stock Split
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that its board of...